Zorana Budakov Obradovic
Research Subjects
Zorana Budakov Obradovic has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jasmina Grujic
Department of Transfusiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
2 shared publications Anna R. E. Robinson
Stanford Biosciences, Stanford School of Medicine, Stanford, CA 94305, USA
1 shared publication- Benedetta Cena
Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
1 shared publication - Benjamin G. Hale
Institute of Medical Virology, University of Zürich, 8057 Zürich, Switzerland
1 shared publication - Biljana Popovska Jovičić
Department of Infectious Diseases, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
1 shared publication - Boris Obrovski
University of Novi Sad
1 shared publication
Latest Publications
- Open Access
Human antibodies against West Nile and related orthoflaviviruses
West Nile virus (WNV) is a mosquito-borne pathogen of global concern that can cause fatal neuroinvasive disease. No specific prophylaxis or treatment exists for WNV or related orthoflavivirus infections, and the determinants of human disease severity remain poorly understood. Here, we report that neutralizing autoantibodies against type I interferons do not impair antiviral antibody development. Among the fully human monoclonal antibodies with potent neutralizing activity against WNV that were discovered, W010 targets a unique epitope within the envelope protein domain III (EDIII) and confers both pre- and post-exposure protection in a murine WNV model, even when interferon signaling is impaired. A second protective antibody, W014, exhibits broad cross-neutralization of other pathogenic orthoflavivirus members, including Japanese encephalitis virus, Murray Valley encephalitis virus, Saint Louis encephalitis virus, and Usutu virus. These findings identify key neutralizing epitopes on WNV EDIII and provide candidates for the development of antibody-based interventions against encephalitic orthoflavivirus infections.
Open AccessHuman antibodies against West Nile and related orthoflaviviruses
West Nile virus (WNV) is a mosquito-borne pathogen of global concern that can cause fatal neuroinvasive disease. No specific prophylaxis or treatment exists for WNV or related orthoflavivirus infections, and the determinants of human disease severity remain poorly understood. Here, we report that neutralizing autoantibodies against type I interferons do not impair antiviral antibody development. Among the fully human monoclonal antibodies with potent neutralizing activity against WNV that were discovered, W010 targets a unique epitope within the envelope protein domain III (EDIII) and confers both pre- and post-exposure protection in a murine WNV model, even when interferon signaling is impaired. A second protective antibody, W014, exhibits broad cross-neutralization of other pathogenic orthoflavivirus members, including Japanese encephalitis virus, Murray Valley encephalitis virus, Saint Louis encephalitis virus, and Usutu virus. These findings identify key neutralizing epitopes on WNV EDIII and provide candidates for the development of antibody-based interventions against encephalitic orthoflavivirus infections.
- 1 April 2024
- Published by Wiley in Transfusion Medicine
- Vol. 34 (3) , 200-210
Reactivity of anti‐SARS‐CoV‐2 antibodies in Serbian voluntary blood donors
Background: The COVID‐19 pandemic has major implications on the entire blood supply system worldwide. Seroepidemiological studies are certainly necessary for better understanding the global burden that the COVID‐19 pandemic represents.Objectives: In this study, we analysed the association between demographic factors, COVID‐19 severity, vaccination status and the reactivity of anti‐SARS‐CoV‐2 IgG antibodies in Serbian blood donors.Materials and Methods: In a prospective study, demographic data and data related to previous SARS‐CoV‐2 infection, COVID‐19 severity and vaccination status among whole blood donors were analysed, from February 10 to August 10, 2022, at the Blood Transfusion Institute of Vojvodina, Serbia. The detection and determination of the level of anti‐SARS‐CoV‐2 IgG antibodies were performed using LIAISON® SARS‐CoV‐2 TrimericS IgG immunoassay.Results: A total of 1190 blood donors were included, 24.5% were female and 75.5% were male while their average age was 41 years. Anti‐SARS‐CoV‐2 antibody values ranged from 2.40 to 3120 BAU/ml with a mean value of 1354.56 BAU/ml. Statistical analysis showed that COVID‐19 severity and vaccination status are linked with reactivity of anti‐SARS‐CoV‐2 antibodies, while gender and age of voluntary blood donors are not related to the values of anti‐SARS‐CoV‐2 antibodies.Conclusion: The values of anti‐SARS‐CoV‐2 antibodies in voluntary blood donors in Serbia are kept relatively high, especially in blood donors who have overcome the severe COVID‐19, as well as in donors who have been vaccinated against COVID‐19. Further SARS‐CoV‐2 seroprevalence studies in our country are certainly still necessary so global strategies to fight against COVID‐19 would be adequately evaluated.
- 1 April 2024
- Published by Wiley in Transfusion Medicine
- Vol. 34 (3) , 200-210
Reactivity of anti‐SARS‐CoV‐2 antibodies in Serbian voluntary blood donors
Background: The COVID‐19 pandemic has major implications on the entire blood supply system worldwide. Seroepidemiological studies are certainly necessary for better understanding the global burden that the COVID‐19 pandemic represents.Objectives: In this study, we analysed the association between demographic factors, COVID‐19 severity, vaccination status and the reactivity of anti‐SARS‐CoV‐2 IgG antibodies in Serbian blood donors.Materials and Methods: In a prospective study, demographic data and data related to previous SARS‐CoV‐2 infection, COVID‐19 severity and vaccination status among whole blood donors were analysed, from February 10 to August 10, 2022, at the Blood Transfusion Institute of Vojvodina, Serbia. The detection and determination of the level of anti‐SARS‐CoV‐2 IgG antibodies were performed using LIAISON® SARS‐CoV‐2 TrimericS IgG immunoassay.Results: A total of 1190 blood donors were included, 24.5% were female and 75.5% were male while their average age was 41 years. Anti‐SARS‐CoV‐2 antibody values ranged from 2.40 to 3120 BAU/ml with a mean value of 1354.56 BAU/ml. Statistical analysis showed that COVID‐19 severity and vaccination status are linked with reactivity of anti‐SARS‐CoV‐2 antibodies, while gender and age of voluntary blood donors are not related to the values of anti‐SARS‐CoV‐2 antibodies.Conclusion: The values of anti‐SARS‐CoV‐2 antibodies in voluntary blood donors in Serbia are kept relatively high, especially in blood donors who have overcome the severe COVID‐19, as well as in donors who have been vaccinated against COVID‐19. Further SARS‐CoV‐2 seroprevalence studies in our country are certainly still necessary so global strategies to fight against COVID‐19 would be adequately evaluated.